JP2013519685A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013519685A5 JP2013519685A5 JP2012553052A JP2012553052A JP2013519685A5 JP 2013519685 A5 JP2013519685 A5 JP 2013519685A5 JP 2012553052 A JP2012553052 A JP 2012553052A JP 2012553052 A JP2012553052 A JP 2012553052A JP 2013519685 A5 JP2013519685 A5 JP 2013519685A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutical composition
- halogen
- composition according
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 50
- 229910052799 carbon Inorganic materials 0.000 claims 26
- 229910052760 oxygen Inorganic materials 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 229910052717 sulfur Inorganic materials 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 23
- 229910052736 halogen Inorganic materials 0.000 claims 22
- 150000002367 halogens Chemical group 0.000 claims 22
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 229910052757 nitrogen Inorganic materials 0.000 claims 16
- 150000002431 hydrogen Chemical group 0.000 claims 12
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000004064 dysfunction Effects 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 108010038422 metabotropic glutamate receptor 4 Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 108010005456 AMPA 4 glutamate receptor ionotropic Proteins 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 102100030668 Glutamate receptor 4 Human genes 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000000848 glutamatergic effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000005062 synaptic transmission Effects 0.000 claims 1
- 0 Nc1ccc2OC*c2c1 Chemical compound Nc1ccc2OC*c2c1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30348110P | 2010-02-11 | 2010-02-11 | |
| US61/303,481 | 2010-02-11 | ||
| PCT/US2011/024627 WO2011100614A1 (en) | 2010-02-11 | 2011-02-11 | BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013519685A JP2013519685A (ja) | 2013-05-30 |
| JP2013519685A5 true JP2013519685A5 (enExample) | 2014-04-03 |
Family
ID=44368169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012553052A Pending JP2013519685A (ja) | 2010-02-11 | 2011-02-11 | ｍＧｌｕＲ４アロステリック増強剤としてのベンズイソオキサゾール類およびアザベンズイソオキサゾール類、組成物、および神経機能不全を治療する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8916584B2 (enExample) |
| EP (1) | EP2533642A4 (enExample) |
| JP (1) | JP2013519685A (enExample) |
| KR (1) | KR20120120416A (enExample) |
| CN (1) | CN102834009A (enExample) |
| AU (1) | AU2011215645A1 (enExample) |
| BR (1) | BR112012020271A2 (enExample) |
| CA (1) | CA2789434A1 (enExample) |
| IL (1) | IL221389A0 (enExample) |
| MX (1) | MX2012009377A (enExample) |
| RU (1) | RU2012139491A (enExample) |
| SG (1) | SG183261A1 (enExample) |
| WO (1) | WO2011100614A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG173465A1 (en) | 2009-01-28 | 2011-09-29 | Univ Vanderbilt | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2013062858A1 (en) * | 2011-10-25 | 2013-05-02 | Merck Sharp & Dohme Corp. | Isoxazolopyridine orexin receptor antagonists |
| US9085517B2 (en) | 2011-12-15 | 2015-07-21 | Pfizer Limited | Sulfonamide derivatives |
| BR112016005994A2 (pt) * | 2013-09-25 | 2017-08-01 | Hoffmann La Roche | derivados de etinila |
| KR101532211B1 (ko) * | 2014-04-30 | 2015-06-30 | 세종대학교산학협력단 | Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물 및 방법 |
| KR20170034439A (ko) | 2014-08-13 | 2017-03-28 | 오클랜드 유니서비시즈 리미티드 | 트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도 |
| US9980945B2 (en) | 2015-01-13 | 2018-05-29 | Vanderbilt University | Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10221172B2 (en) | 2015-01-13 | 2019-03-05 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016123627A1 (en) | 2015-01-30 | 2016-08-04 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction |
| US10526323B2 (en) | 2015-01-30 | 2020-01-07 | Vanderbilt University | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016179351A1 (en) | 2015-05-05 | 2016-11-10 | Northwestern University | Treatment of levodopa-induced dyskinesias |
| CN104974103A (zh) * | 2015-07-14 | 2015-10-14 | 佛山市赛维斯医药科技有限公司 | 一类含苯并异恶唑和烷氧苯基类结构的化合物及其用途 |
| CN104926745A (zh) * | 2015-07-14 | 2015-09-23 | 佛山市赛维斯医药科技有限公司 | 含苯并异恶唑和末端卤代苄基类结构的化合物及其用途 |
| US11414428B2 (en) | 2015-08-27 | 2022-08-16 | Auckland Uniservices Limited | Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy |
| US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11319304B2 (en) | 2017-06-28 | 2022-05-03 | Vanderbilt University | Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| BR112020003292A2 (pt) | 2017-08-16 | 2020-08-18 | Vanderbilt University | compostos indazol como potencializadores alostéricos de mglur4 e seus usos terapêuticos, bem como composição farmacêutica e método para fabricação de medicamento para potenciar a atividade do receptor mglur4 |
| EP3897630B1 (en) | 2018-12-21 | 2024-01-10 | Celgene Corporation | Thienopyridine inhibitors of ripk2 |
| JP2022534704A (ja) | 2019-06-04 | 2022-08-03 | ヘイガー バイオサイエンシズ，エルエルシー | オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2811527A (en) * | 1955-11-16 | 1957-10-29 | Olin Mathieson | Derivatives of thieno (3, 2-b) pyridine and method of preparing same |
| US5252581A (en) | 1992-07-20 | 1993-10-12 | Hoechst-Roussel Pharmaceuticals Inc. | Substituted aminothienopyridines, pharmaceutical composition and use |
| HU221138B1 (en) | 1994-08-30 | 2002-08-28 | Sankyo Co | Condensed isoxazolyloxy- and -thioalkylamine derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| US6506747B1 (en) | 1998-06-05 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
| WO2000010454A1 (en) | 1998-08-24 | 2000-03-02 | Ctf Systems Inc. | Functional brain imaging from magnetoencephalographic data |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| WO2001087845A2 (en) * | 2000-05-15 | 2001-11-22 | Fujisawa Pharmaceutical Co., Ltd. | N-containing heterocyclic compounds and their use as 5-ht antagonists |
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7368285B2 (en) * | 2001-03-07 | 2008-05-06 | Senomyx, Inc. | Heteromeric umami T1R1/T1R3 taste receptors and isolated cells that express same |
| US6593349B2 (en) | 2001-03-19 | 2003-07-15 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| US7160913B2 (en) * | 2002-09-13 | 2007-01-09 | Thomas Jefferson University | Methods and kit for treating Parkinson's disease |
| PL376789A1 (pl) | 2002-12-12 | 2006-01-09 | Aventis Pharma S.A. | Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| RU2357957C2 (ru) | 2003-03-03 | 2009-06-10 | Эррэй Биофарма, Инк. | Ингибиторы р38 и способы их применения |
| EP1646377A4 (en) * | 2003-07-11 | 2009-09-09 | Merck & Co Inc | TREATMENT OF MOVEMENT DISORDERS WITH METABOTROPIC GLUTAMATE 4 RECEPTOR POSITIVE ALLOSTERIC MODULATOR |
| US7625932B2 (en) | 2003-10-08 | 2009-12-01 | Eli Lilly And Company | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors |
| CN101203500B (zh) | 2005-01-25 | 2013-08-21 | 格利尼公司 | 取代的芳胺化合物和它们作为5-ht6调节剂的用途 |
| KR20070097590A (ko) * | 2005-01-25 | 2007-10-04 | 에픽스 델라웨어, 인코포레이티드 | 치환된 아릴아민 화합물 및 5―ｈｔ6 조절제로서의 이의용도 |
| CA2598531A1 (en) | 2005-02-24 | 2006-08-31 | Merck & Co., Inc. | Benzazole potentiators of metabotropic glutamate receptors |
| DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
| WO2008011110A2 (en) | 2006-07-20 | 2008-01-24 | Amgen Inc. | Di-amino-substituted heterocyclic compounds and methods of use |
| ES2338278T3 (es) * | 2006-07-20 | 2010-05-05 | Amgen Inc. | Derivados de benzo(d)isoxazol como inhibidores de c-kit tirosina quinasa para el tratamiento de enfermedades asociadas con la sobreproduccion de histamina. |
| WO2008089307A2 (en) * | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer |
| US20080200458A1 (en) * | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
| MX2009008872A (es) * | 2007-02-20 | 2009-10-30 | Novartis Ag | Compuestos macrociclicos como inhibidores de proteasa ns3 del virus de hepatitis c. |
| GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
-
2011
- 2011-02-11 BR BR112012020271A patent/BR112012020271A2/pt not_active IP Right Cessation
- 2011-02-11 RU RU2012139491/04A patent/RU2012139491A/ru not_active Application Discontinuation
- 2011-02-11 KR KR1020127023700A patent/KR20120120416A/ko not_active Withdrawn
- 2011-02-11 EP EP11742914.2A patent/EP2533642A4/en not_active Withdrawn
- 2011-02-11 CN CN201180017220XA patent/CN102834009A/zh active Pending
- 2011-02-11 WO PCT/US2011/024627 patent/WO2011100614A1/en not_active Ceased
- 2011-02-11 US US13/578,802 patent/US8916584B2/en active Active
- 2011-02-11 MX MX2012009377A patent/MX2012009377A/es not_active Application Discontinuation
- 2011-02-11 SG SG2012059309A patent/SG183261A1/en unknown
- 2011-02-11 JP JP2012553052A patent/JP2013519685A/ja active Pending
- 2011-02-11 CA CA2789434A patent/CA2789434A1/en not_active Abandoned
- 2011-02-11 AU AU2011215645A patent/AU2011215645A1/en not_active Abandoned
-
2012
- 2012-08-09 IL IL221389A patent/IL221389A0/en unknown